objective: the current study aimed to determine the efficacy of radioiodine-131 (131i) ablation therapy with thyroid hormone replacement one day before 131i administration in patients with well-differentiated thyroid cancer (dtc). methods: this retrospective study included 29 patients who underwent 131i therapies twice for dtc during 6-12 months.  since all the patients obviously had residual l...

Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months.  Since all the patients obviously had residual l...

Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, 131I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP-131I) to evaluate their cell uptake activity, in vivo blood circulation...

Objective: The aim of this study was to explore the clinical characteristics of renal metastatic cancer, the methods for its detection by radioiodine (131I), and the response to 131I treatment in fourteen patients with renal metastases from differentiated thyroid carcinoma (DTC). Subjects and methods: DTC patients (n = 2,955) that received treatment with 131I were retrospectively analyzed. Scan...

The role of thallium-201 (201TI) scintigraphy in the follow-up evaluation of differentiated thyroid carcinoma (DTC) is controversial. Desirable characteristics of 201TI scintigraphy including the potential for no thyroid hormone withdrawal, immediate imaging postinjection, and low radiation burden relative to iodine-131 (131I) suggests it is logistically superior to 131I scintigraphy. Fifty-two...

OBJECTIVE Dosimetry studies have shown that activities of 131I as small as 10-20 MBq may cause a stunning effect. A result of this stunning effect may be a lower success rate of the ablative 131I therapy for differentiated thyroid carcinoma (DTC). The aim of this study was to determine whether pre-therapeutic uptake measurement with 40 MBq 131I causes a lower success rate of ablation. DESIGN ...

The conventional course of differentiated thyroid cancer (DTC) treatment requires surgical resection followed by radioactive iodine (131I) therapy (RAIT). Patients are advised to drink plenty water, as 131I gets eliminated through the kidneys and burden extra radiation is reduced. Treating a case DTC with chronic kidney disease (CKD) RAIT challenging. As result, when planning hemodialysis in pa...

Background: Anti-thyroid drugs (ATD) are routinely used in Australian practice as first-line therapy for Graves’ hyperthyroidism (GH) prior to 131I (radioiodine) treatment. There is concern that patients who do not receive ATD pre-treatment will develop uncontrolled hyperthyroidism before and after 131I therapy and that 131I therapy without ATD pre-treatment may not be as efficacious as with AT...